Status:

Grey, Grey - after consultant/specialist recommendation, Red

Decision Date:

July 2024

Comments

GREY - for treating type 2 diabetes only as an alternative to GLP-1 agonist for patients with type 2 diabetes who require triple therapy if alternative GLP-1s are not tolerated by patient, not efficacious or not available due to stock issues.  (Decision date July 2024)

• 2.5mg and 5mg pens
• NICE TA924 - Tirzepatide (Mounjaro) for treating type 2 diabetes.

• Not all GLP-1s are equally tolerated, if a patient is unable to tolerate the first choice GLP-1, try alternative GLP-1 agonist (if available) before considering tirzepatide.
• For further information please see the Management of Type 2 Diabetes in Adults prescribing guideline

 

GREY after specialist recommendation - 

• Doses over 5mg (7.5mg, 10mg, 12.5mg and 15mg pens)  (Decision date - August 2024) 

 

RED: TA1026: Tirzepatide for managing overweight and obesity (Decision date January 2025)

 

 

Grey Drug Classifications

• 5: Less cost-effective than current standard therapy

Grey Drug Classifications

• 5: Less cost-effective than current standard therapy

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
• 5: Is new to clinical practice and unfamiliar, necessitating a period of accumulation of experience, firstly (and most rapidly) by consultants/specialists

search again